SELLAS succeeds in mid-stage study for myeloid leukemia treatment
Source: SeekingAlpha
2025-04-08 11:47:26 ET
More on SELLAS Life Sciences
- Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst
- SELLAS Life Sciences GAAP EPS of -$0.50 beats by $0.04
- SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
- Seeking Alpha’s Quant Rating on SELLAS Life Sciences
- Historical earnings data for SELLAS Life Sciences
Read the full article on Seeking Alpha
For further details see:
SELLAS succeeds in mid-stage study for myeloid leukemia treatment
SELLAS Life Sciences Group Inc.
NASDAQ: SLS
SLS Trading
1.87% G/L:
$7.1001 Last:
1,530,172 Volume:
$7.16 Open:
SLS Latest News
May 12, 2026 04:05:00 pm
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMarch 19, 2026 04:05:00 pm
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate UpdateSLS Stock Data
$535,597,063
140,448,048
1.12%
50
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
